Exon 19 deletion and exon 21 L858R sensitizing EGFR mutations constitute 86% of EGFR mutations in NSCLC and confer high responsiveness (sensitivity) to EGFR tyrosine kinase inhibitors (TKIs) [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.